CANNABIS
Dronabinol effective in reducing central lesion pain from multiple sclerosis after 3-week treatment
BMJ. 2004 Jul 31;329(7460):25324 patients experiencing central lesion pain due to multiple sclerosis were randomly assigned to receive either dronabinol (maximum of 5mg twice per day) or placebo for 3 weeks. They then underwent a washout period of at least 3 weeks, and were crossed-over to receive the other intervention for 3 weeks. Patients were assessed on the median spontaneous pain intensity, radiating pain intensity, pain relief, health-related quality of life, various quantitative sensitization tests, and the incidence of adverse events. Results demonstrated dronabinol treatment efficacy in reducing spontaneous pain intensity, radiating pain intensity, and pressure-evoked pain. Dronabinol treatment also raised more adverse events than placebo, but no adverse events led to study drop-out.
Unlock the full ACE Report
You have access to {0} free articles per month.Click below to unlock and view this {1}
Unlock NowCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
Already have an account? Log in
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
{0} of {1} free articles
Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.
Upgrade Now
